Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00072722
Recruitment Status : Completed
First Posted : November 13, 2003
Last Update Posted : December 19, 2006
Sponsor:
Information provided by:
Celgene

Brief Summary:
Phase II randomized open-label, two-arm study of safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer (HRPC)

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: CC-4047 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
Study Start Date : September 2003
Study Completion Date : April 2005

Resource links provided by the National Library of Medicine






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Understand and voluntarily sign an informed consent form
  • Adult male subjects, age 18 or older at the time of signing the informed consent form
  • Able to adhere to the study visit schedule and other protocol requirements
  • Histologically confirmed adenocarcinoma of the prostate with radiographic evidence of metastases and PSA progression following hormonal therapy for metastatic disease. Subjects must have evidence of progression of disease as demonstrated by 2 consecutive rises in PSA (an absolute change of at least 1ng/ml) separated by at least 28 days.
  • Antiandrogen therapy must have been stopped at least 4 weeks (for flutamide) or 6 weeks (for bicalutamide or nilutamide) prior to entering study with evidence of a rising PSA (from baseline) measured x 2 at least 2 weeks apart Testicular androgen suppression must be maintained with either LHRH therapy of bilateral orchiectomy.
  • Must use barrier contraception (latex condom) when engaging in reproductive activity with women of child-bearing potential throughout the course of study treatment and for 4 weeks following the discontinuation of study treatment.
  • May have had only one prior regimen of chemotherapy for prostate cancer. The chemotherapy must have been stopped at least 4 weeks prior to study entry.
  • Disease-free of other malignancies for greater than 5 years with the exception of curatively treated basal cell, squamous cell carcinoma of the skin of Ta transitional cell carcinoma of the bladder.
  • ECOG performance status of 0 or 1.
  • Serum creatinine greater than or equal to 2.0 mg%
  • Adequate hematologic functions: Granulocytes greater than or equal to 1800 mm3 and platelets greater than or equal to 100,000 mm3.
  • Adequate hepatocellular function: AST<2 x normal and bilirubin<1.5mg/dl
  • No active unresolved infection

Exclusion Criteria:

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study or confounds the ability to interpret data from the study.
  • Use of any other experimental drug or therapy within 28 days of baseline.
  • Any prior use of CC-4047 of Thalidomide
  • Tumors containing small cell or sarcomatoid elements
  • Symptomatic bone metastases.
  • Concurrent use of any other anti-cancer agents.
  • Known brain disease that is symptomatic, is currently being treated with corticosteroids, or has not been previously irradiated.
  • Non-PSA producing tumors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00072722


Locations
Layout table for location information
United States, Colorado
University of Colorado Health Science Center
Denver, Colorado, United States, 80220-3706
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Celgene Corporation

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00072722     History of Changes
Other Study ID Numbers: CC-4047-PC-002
First Posted: November 13, 2003    Key Record Dates
Last Update Posted: December 19, 2006
Last Verified: December 2006

Keywords provided by Celgene:
Prostate Cancer
Metastatic Hormone Refractory Prostate Cancer
CC4047
CC-4047
Prostate Carcinoma
Celgene

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Thalidomide
Pomalidomide
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunologic Factors
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Immunosuppressive Agents
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents